Compound: pimobendan
SMILES: O=C1NN=C(c2cc3[nH]c(-c4ccc(OC)cc4)nc3cc2)C(C1)C
InChIKey: GLBJJMFZWDBELO-UHFFFAOYSA-N
Synonyms: pimobendan, 74150-27-9, pimobendane, Acardi, dl-Pimobendan, Vetmedin, Pimobendanum, UD-CG-115BS, Racemic pimobendan, UD-CG-115, UDCG-115, 34AP3BBP9T, DTXSID8048280, CHEBI:32003, FORTEKOR PLUS COMPONENT PIMOBENDAN, 3(2H)-Pyridazinone, 4,5-dihydro-6-(2-(4-methoxyphenyl)-1H-benzimidazol-5-yl)-5-methyl-, 6-[2-(4-methoxyphenyl)-1H-benzimidazol-5-yl]-5-methyl-4,5-dihydropyridazin-3(2H)-one, UD-CG115, Pimobendan,USP, Vetmedin Solution, Pimobendan EP5, 6-(2-(4-methoxyphenyl)-1H-benzimidazol-5-yl)-5-methyl-4,5-dihydropyridazin-3(2H)-one, Vetmedin-CA1, RefChem:55860, SolutitionKits Pimobendan, DTXCID9028255, 4,5-dihydro-6-(2-(4-methoxyphenyl)-1H-benzimidazole-5-yl)-5-methyl-3(2H)-pyridazinone, d-Pimobendan, Pimobendan, (-)-, (-)-Pimobendan, l-Pimobendan, 118428-37-8, (+)-Pimobendan, 6-(2-(4-METHOXYPHENYL)-1H-BENZO[D]IMIDAZOL-5-YL)-5-METHYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE, Pimobendan, (+)-, Pimobendan (Vetmedin), MFCD00761648, 3-[2-(4-methoxyphenyl)-3H-benzimidazol-5-yl]-4-methyl-4,5-dihydro-1H-pyridazin-6-one, 118428-38-9, rac Pimobendan, BRN 4207330, CHEMBL24646, 613JXV89SU, 9HTU209Z0N, 3(2H)-Pyridazinone, 4,5-dihydro-6-(2-(4-methoxyphenyl)-1H-benzimidazol-5-yl)-5-methyl-, (+)-, 3(2H)-Pyridazinone, 4,5-dihydro-6-(2-(4-methoxyphenyl)-1H-benzimidazol-5-yl)-5-methyl-, (-)-, Racemic pinobendan, UD-CG 115, UD-CG 115 BS, Pimobendan [INN-Spanish], Pimobendane [INN-French], Pimobendanum [INN-Latin], (+)-UD-CG 115BS, (-)-UD-CG 115BS, NCGC00274063-01, UNII-34AP3BBP9T, UNII-613JXV89SU, UNII-9HTU209Z0N, Pimobendam, Pimobendan [USAN:INN:BAN], Pimobendan?, 4,5-Dihydro-6-[2-(4-methoxyphenyl)-1H-benzimidazol-5-yl]-5-methyl-3(2H)-pyridazinone, Pimobendan CRS, GLBJJMFZWDBELO-UHFFFAOYSA-N, Acardi (TN), Pimobendan (Standard), PIMOBENDAN [MI], PIMOBENDAN [INN], PIMOBENDAN [JAN], PIMOBENDAN [USAN], PIMOBENDAN [MART.], (+)-4,5-Dihydro-6-(2-(4-methoxyphenyl)-1H-benzimidazol-5-yl)-5-methyl-3(2H)-pyridazinone, (-)-4,5-Dihydro-6-(2-(4-methoxyphenyl)-1H-benzimidazol-5-yl)-5-methyl-3(2H)-pyridazinone, 6-(2-(4-Methoxyphenyl)-4,5-dihydro-1H-benzimidazol-5-yl)-5-methyl-3(2H)-pyridazinone, PIMOBENDAN [USP-RS], PIMOBENDAN [WHO-DD], SCHEMBL27623, MLS006010188, Pimobendan (JAN/USAN/INN), orb1307669, orb1695666, SCHEMBL1649737, PIMOBENDAN [GREEN BOOK], PIMOBENDAN [EP IMPURITY], Pimobendan, >=98% (HPLC), SCHEMBL29386190, HY-B0204R, GLXC-07557, HMS3655I03, HMS3884C21, HMS5079O14, KUC109647N, PIMOBENDAN [USP MONOGRAPH], HY-B0204, MSK14881, AC-689, BDBM50282617, s1550, AKOS015851937, AKOS015967705, CCG-267853, DB11450, EBC-130025, FP38260, KS-1280, KSC-210-009, PIMOBENDAN [EMA EPAR VETERINARY], NCGC00274063-04, NCGC00274063-05, 118428-36-7, Pimobendan 100 microg/mL in Acetonitrile, SMR002530068, SY122254, DB-219709, P2779, Pimobendan for veterinary use [ep monograph], SW219717-1, D01133, SBI-0654181.0001, AB01274800-01, AB01274800_02, EN300-27067685, Q414351, BRD-A84575140-001-02-4, Pimobendan, United States Pharmacopeia (USP) Reference Standard, 4,5-dihydro-6-[2-(4-methoxy-phenyl)-1h-benzimidazol-5-yl]-5-methyl-3 (2h)-pyridazinone, 4,5-Dihydro-6-[2-(4-methoxyphenyl)-1H-benzimidazol-6-yl]-5-methyl-3(2H)-pyridazinone, 6-[2-(4-Methoxyphenyl)-3H-benzimidazol-5-yl]-5-methyl-4,5-dihydro-2H-pyridazin-3-one, Pimobendan for system suitability, European Pharmacopoeia (EP) Reference Standard, (+/-)-4,5-DIHYDRO-6-(2-(P-METHOXYPHENYL)-5-BENZIMIDAZOLYL)-5-METHYL-3(2H)-PYRIDAZINONE, (5RS)-6-[2-(4-Methoxyphenyl)-1H-benzimidazol-5-yl]-5- methyl-4,5-dihydropyridazin-3(2H)-one, 3(2H)-PYRIDAZINONE, 4,5-DIHYDRO-6-(2-(4-METHOXYPHENYL)-1H-BENZIMIDAZOL-5-YL)-5-METHYL-, (+/-)-, 3(2H)-PYRIDAZINONE, 4,5-DIHYDRO-6-(2-(4-METHOXYPHENYL)-1H-BENZIMIDAZOL-6-YL)-5-METHYL-, 6-[2-(4-Methoxyphenyl)-1H-1,3-benzimidazol-6-yl]-5-methyl-4,5-dihydropyridazin-3(2H)-one, 6-[2-(4-methoxyphenyl)-1H-1,3-benzodiazol-6-yl]-5-methyl-2,3,4,5-tetrahydropyridazin-3-one
Theoretical properties:
molecular_formula: C19H18N4O2
molecular_weight: 334.4 g/mol
exact_mass: 334.14297583 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 2
hydrogen_bond_acceptor_count: 4
rotatable_bond_count: 3
heavy_atom_count: 25
topological_polar_surface_area: 79.4 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
Descriptions:
pubchem: Pimobendan is a member of benzimidazoles and a pyridazinone. It has a role as a vasodilator agent, a cardiotonic drug and an EC 3.1.4.* (phosphoric diester hydrolase) inhibitor.
chembl: PIMOBENDAN is a small molecule listed in the ChEMBL database and has reached clinical trial phase 2.0.
wikipedia: Pimobendan (INN, or pimobendane), sold under the brand name Vetmedin among others, is a veterinary medication. It is a calcium sensitizer and a selective inhibitor of phosphodiesterase 3 (PDE3) with positive inotropic and vasodilator effects.
Pimobendan is used in the management of heart failure in dogs, most commonly caused by myxomatous mitral valve disease (also previously known as endocardiosis), or dilated cardiomyopathy. Research has shown that as a monotherapy, pimobendan increases survival time and improves quality of life in canine patients with congestive heart failure secondary to mitral valve disease when compared with benazepril, an ACE inhibitor. Under the brand name Acardi, it is available for human use in Japan. It is available as a generic medication.